Artwork

内容由Audioboom and Not So Different: a Podcast from The Center for Biosimilars提供。所有播客内容(包括剧集、图形和播客描述)均由 Audioboom and Not So Different: a Podcast from The Center for Biosimilars 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

S5 Ep5: Biosimilars Regulatory Roundup for August 2022—Podcast Edition

4:37
 
分享
 

Manage episode 340100952 series 2161808
内容由Audioboom and Not So Different: a Podcast from The Center for Biosimilars提供。所有播客内容(包括剧集、图形和播客描述)均由 Audioboom and Not So Different: a Podcast from The Center for Biosimilars 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Opinion: The Inflation Reduction Act is a Step Backward for Biosimilar Competition
https://www.centerforbiosimilars.com/view/opinion-the-inflation-reduction-act-is-a-step-backward-for-biosimilar-competition



FDA Approves Coherus’ Cimerli as Interchangeable Biosimilar to Ranibizumab
https://www.centerforbiosimilars.com/view/fda-approves-coherus-cimerli-as-interchangeable-biosimilar-to-ranibizumab

FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar


Eye on Pharma: Celltrion Aims for Adalimumab Interchangeability; Phase 3 Results for Ustekinumab Biosimilar
https://www.centerforbiosimilars.com/view/eye-on-pharma-celltrion-aims-for-adalimumab-interchangeability-phase-3-results-for-ustekinumab-biosimilar


  continue reading

153集单集

Artwork
icon分享
 
Manage episode 340100952 series 2161808
内容由Audioboom and Not So Different: a Podcast from The Center for Biosimilars提供。所有播客内容(包括剧集、图形和播客描述)均由 Audioboom and Not So Different: a Podcast from The Center for Biosimilars 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal

Opinion: The Inflation Reduction Act is a Step Backward for Biosimilar Competition
https://www.centerforbiosimilars.com/view/opinion-the-inflation-reduction-act-is-a-step-backward-for-biosimilar-competition



FDA Approves Coherus’ Cimerli as Interchangeable Biosimilar to Ranibizumab
https://www.centerforbiosimilars.com/view/fda-approves-coherus-cimerli-as-interchangeable-biosimilar-to-ranibizumab

FDA Approves High-Concentration Formulation of Samsung Bioepis’ Humira Biosimilar


Eye on Pharma: Celltrion Aims for Adalimumab Interchangeability; Phase 3 Results for Ustekinumab Biosimilar
https://www.centerforbiosimilars.com/view/eye-on-pharma-celltrion-aims-for-adalimumab-interchangeability-phase-3-results-for-ustekinumab-biosimilar


  continue reading

153集单集

所有剧集

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南

边探索边听这个节目
播放